The objective of this study was to evaluate the evidence on cost‐effectiveness of
pharmacogenetic (PGx)–guided treatment for drugs with Clinical Pharmacogenetics …

Pharmacogenetics (PGx) has the potential to personalize pharmaceutical treatments. Many
relevant gene–drug associations have been discovered, but PGx-guided treatment needs to …

Background Pharmacogenetics offers the potential to improve health outcomes by
identifying individuals who are at greater risk of harm from certain medicines. Routine …

Background Unverified penicillin allergy leads to adverse downstream clinical and
economic sequelae. Penicillin allergy evaluation can be used to identify true, IgE-mediated …

The major challenges that delay the implementation of pharmacogenomics based clinical
practice in the developing countries, primarily the low-and middle-income countries need to …

Adverse drug reactions (ADRs) are common, are associated with morbidity and mortality,
and are costly to healthcare systems. Genomic factors predispose to ADRs, but these vary …

Introduction: Pharmacogenomic testing has the potential to greatly benefit patients by
enabling personalization of medication management, ensuring better efficacy and …

Abstract The Singapore Integrative Omics Study provides valuable insights on establishing
population reference measurement in 364 Chinese, Malay, and Indian individuals. These …

A clinical association between a specific human leukocyte antigen (HLA) allele and
idiosyncratic adverse drug reactions (IADRs) is a strong indication that IADRs are mediated …

Pharmacogenomics has been lauded as an important innovation in clinical medicine as a
result of advances in genomic science. As one of the cornerstones in precision medicine, the …